Riociguat

Riociguat Riociguat is a soluble guanylate cyclase stimulator useful in the treatment of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH). CHEST-1 trial was a phase 3, multicenter, randomized, double blind, placebo controlled study [1]. 261 patients with inoperable chronic thromboembolic pulmonary hypertension or persistent or recurrent pulmonary hypertension after pulmonary endarterectomy were randomly assigned to receive either placebo or riociguat. Primary end point of the study was the change in 6 minute walk distance from baseline to the end of 16th week. Secondary end points were change in pulmonary vascular resistance, NT-proBNP level, WHO functional class, time to clinical worsening, Borg dyspnea score, quality of life variables and safety. 6 minute walk distance increased by a mean of 39 m in the riociguat group as compared to a mean decrease of 6 m in the placebo group. Pulmonary vascular resistance decreased by 226 dyn·sec·cm–5 in the riociguat group while it increased by 23 dyn·sec·cm–5 in the placebo group. Significant improvements were noted in NT-proBNP level and WHO functional class. Serious adverse events were similar in both groups. CHEST-2 was an open-label extension of CHEST-1 study, which evaluated the long-term safety and efficacy of riociguat [2]. 237 patients entered CHEST-2 and 211 (89%) were ongoing at the interim analysis in March 2013. There were no new safety signals noted in CHEST-2. Improvem...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardiology Source Type: blogs